WENDY DINAPOLI: Open Payments
NPI 1457059024 · MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 48 payments from 13 companies in 2025. Trend: 2023 $410 · 2024 $1,083 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $391 |
| Phathom Pharmaceuticals, Inc. | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Ipsen Biopharmaceuticals, Inc | 2 | $59 |
| Ardelyx, Inc. | 2 | $54 |
| Janssen Biotech, Inc. | 2 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Novo Nordisk Inc | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Exact Sciences Corporation | 1 | $25 |
Products named: RINVOQ, LINZESS, MAVYRET, VOQUEZNA, IQIRVO, IBSRELA, TREMFYA, XIFAXAN.
Industry payments across FL — which companies pay providers there.
